Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)
Beyond Air, Inc. (XAIR)
Company Research
Source: GlobeNewswire
– Ongoing Phase 1a first-in-human clinical trial continues to demonstrate proof of concept for the UNO solid tumor platform with observed early tumor responses and clinical resolution of radiation dermatitis – Phase 1a data continue to support feasibility of administering UNO at ultra-high concentrations with immune biomarkers at 50,000 parts per million (ppm) demonstrating an immunogenic response – Phase 1b protocol of UNO in combination with anti-PD-1 antibody therapy filed for regulatory approval – Phase 1a clinical data and Phase 1b study design unveiled at 2024 American Society of Oncology Annual Meeting HAMILTON, Bermuda, June 03, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announced encouraging first-in-class clinical data demonstrating evidence of immune system activation via biomarker response in a heavily pretreated p
Show less
Read more
Impact Snapshot
Event Time:
XAIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XAIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XAIR alerts
High impacting Beyond Air, Inc. news events
Weekly update
A roundup of the hottest topics
XAIR
News
- Beyond Air, Inc. (NASDAQ: XAIR) had its price target lowered by analysts at Piper Sandler from $7.00 to $3.50. They now have an "overweight" rating on the stock.MarketBeat
- Beyond Air fires 20% of staff as revenue guidance for LungFit falls [Yahoo! Finance]Yahoo! Finance
- Beyond Air, Inc. (NASDAQ: XAIR) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.MarketBeat
- Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
XAIR
Earnings
- 6/24/24 - Miss
XAIR
Sec Filings
- 6/27/24 - Form 8-K
- 6/24/24 - Form 10-K
- 6/18/24 - Form 8-K
- XAIR's page on the SEC website